These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25657335)

  • 21. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
    Yadav S; van Vlerken LE; Little SR; Amiji MM
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel].
    Yan XJ; Liang LZ; Zeng ZY; Shi Z; Fu LW
    Ai Zheng; 2006 Apr; 25(4):398-403. PubMed ID: 16613669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel.
    Togashi K; Okada M; Yamamoto M; Suzuki S; Sanomachi T; Seino S; Yamashita H; Kitanaka C
    Anticancer Res; 2018 Aug; 38(8):4535-4542. PubMed ID: 30061219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
    Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
    Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells.
    Karami H; Baradaran B; Esfahani A; Estiar MA; Naghavi-Behzad M; Sakhinia M; Sakhinia E
    Asian Pac J Cancer Prev; 2013; 14(12):7719-24. PubMed ID: 24460358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel.
    Khan Z; Khan N; Varma AK; Tiwari RP; Mouhamad S; Prasad GB; Bisen P
    Curr Cancer Drug Targets; 2010 Nov; 10(7):660-9. PubMed ID: 20578991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
    Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
    J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.
    Risnayanti C; Jang YS; Lee J; Ahn HJ
    Sci Rep; 2018 May; 8(1):7498. PubMed ID: 29760419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
    Wang X; Wu E; Wu J; Wang TL; Hsieh HP; Liu X
    PLoS One; 2013; 8(6):e65686. PubMed ID: 23762410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Influence of short hairpin RNA on survivin mRNA expression and chemosensitivity to paclitaxel in ovarian cancer cells].
    Yan XJ; Liang LZ; Zeng ZY; Fu LW; Shi Z
    Zhonghua Fu Chan Ke Za Zhi; 2005 Sep; 40(9):609-13. PubMed ID: 16202317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
    Shuang T; Wang M; Shi C; Zhou Y; Wang D
    FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.
    Riehle R; Pattni B; Jhaveri A; Kulkarni A; Thakur G; Degterev A; Torchilin V
    Pharm Res; 2016 Jul; 33(7):1587-601. PubMed ID: 26951567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
    Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
    PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KLF5 strengthens drug resistance of ovarian cancer stem-like cells by regulating survivin expression.
    Dong Z; Yang L; Lai D
    Cell Prolif; 2013 Aug; 46(4):425-35. PubMed ID: 23869764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.
    Yin T; Wang P; Li J; Wang Y; Zheng B; Zheng R; Cheng D; Shuai X
    Biomaterials; 2014 Jul; 35(22):5932-43. PubMed ID: 24746965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
    Shi Y; Zhang J; Liu M; Huang Y; Yin L
    J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
    Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
    Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
    Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.
    Vivas-Mejia PE; Rodriguez-Aguayo C; Han HD; Shahzad MM; Valiyeva F; Shibayama M; Chavez-Reyes A; Sood AK; Lopez-Berestein G
    Clin Cancer Res; 2011 Jun; 17(11):3716-26. PubMed ID: 21512144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
    Promkan M; Liu G; Patmasiriwat P; Chakrabarty S
    Int J Cancer; 2009 Dec; 125(12):2820-8. PubMed ID: 19551867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.